|
Belehradek M et al., Cancer 1993 [20]
|
Phase I/II
|
8
|
57
|
15
|
73
| | |
|
Allegretti JP et al., Laryngosc, 2001 [16]
|
Phase I/II
|
14
|
51
|
36
|
87
| | |
|
Burian M et al., Acta Otolaringol 2003 [21]
|
Phase II
|
12
|
83
|
17
|
100
| | |
|
Bloom DC et al., Eur J Sur Oncol 2005 [22]
|
Phase II
|
54
|
25
|
32
|
57
| | |
|
Matthiesen LW et al., 2011[23]
|
Phase II
|
3
| | | | |
BLM i.t.&i.v.
|
|
Landstrom FJ et al., Acta Otolaryngol, 2011 [24]
| |
15
| | | |
24
|
BLM i.t.
|
|
Skarlatos I et al., 2011 [25]
|
Prospective multicenter
|
14
|
9 (64.2)
|
4 (28.5)
|
13 (92.8)
|
Nd
|
BLM i.t.&i.v.
|
|
Gargiulo M et al., Ann Surg, 2012 [26]
|
Retrospective
|
13
|
8 (61.5)
|
5 (38.4)
|
13 (100)
|
18 (range 4–48)
|
BLM i.v.
|
|
Mevio N, et al., Tumori, 2012 [27]
|
Prospective
|
13
|
7 (53.8)
|
4 (38.4)
|
11 (84.6)
|
8 (range 2–20)
|
BLM i.v.
|
|
Benevento R et al., Surgery 2013 [28]
|
Prospective
|
8
|
5 (50%)
|
3 (30%)
|
8 (100)
|
3
|
BLM i.v.
|
|
Solari N et al., J Surg Oncol, 2014[29]
|
Prospective
|
5
|
Nd
| | |
6
|
BLM i.v.
|
|
Seccia V et al., Anticancer Res, 2014 [30]
|
Prospective
|
8
|
2 (25)
|
5 (62)
|
7 (87)
|
9 (range 3–12)
|
BLM i.v.
|
|
Campana LG et al., Br J Oral Maxillofac Surg, 2014 [31]
|
Retrospective
|
24
|
6 (25)
|
6 (25)
|
12 (50)
|
14 (3–82)
|
BLM i.t.&i.v.
|
|
Landstorm FJ et al., Acta Otolaryngol, 2015 [32]
| |
4
|
4
| |
4
|
24
|
BLM i.t.
|
|
Landstorm FJ et al., Acta Otolaryngol, 2015 [33]
|
Prospective
|
18
|
Nd
| |
(100)
|
Median 58 months
|
BLM i.t.
|
|
Domanico R et al., Drug Des Devel Ther, 2015 [34]
|
Experimental
|
4
|
0
|
3 (75)
|
3 (75)
|
1
|
BLM i.v.
|
|
Campana LG et al., EJSO, 2016 [18]
|
Prospective multicenter
|
35
|
14 (40.7%)
|
21 (60)
|
30 (85.2)
|
1–12 (evaluation at 2 months)
|
BLM i.v.&i.t., CDDP i.t.
|
|
Rotunno R et al., G It Derm Venereol, 2015[35]
|
Multicenter prospective not randomized phase II
|
25
|
13 (52)
|
7 (28)
|
20 (80)
|
13
|
BLM i.v.
|
|
Bertino G et al. Eur J Cancer, 2016 [36]
|
Prospective multi center
|
50
|
26/47 (55)
|
11/47 (24)
|
37/47 (79)
|
2
|
BLM i.t.&i.v.
|
|
Di Monta G et al., current study
|
Retrospective
|
22
|
22.7
|
59
|
81.7
|
34 (range 5–48)
|
BLM i.v.
|
